Preparing the trial collection…
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
OCD trial landscape

Psilocybin Clinical Trials for OCD

Review registry records that explicitly study psilocybin in obsessive-compulsive disorder and closely matching registered condition labels.

Explore this trial map All recruiting trials

Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.

10matching trials
3currently recruiting
12registry-listed sites

Registry facts checkedAug 10, 2026 01:26 UTC

Live registry synthesis

Status, geography, and study phase

This is a deliberately narrow collection based on registry condition fields. Small counts reflect the indexed evidence landscape and are not expanded with loosely related diagnoses.

Recruitment status

  1. Active, not recruiting3
  2. Recruiting3
  3. Completed3
  4. Terminated1

Leading countries

  1. United States7
  2. Canada1
  3. Israel1
  4. United Kingdom1

Trial phases

  1. Phase 17
  2. Early Phase 11
  3. Phase 21
Interactive map

Explore matching study locations

The map opens with this collection’s filter applied. Its controls can further narrow status, phase, condition, country, intervention, and dates.

Open full map
Server-rendered source index

10 matching registry records

Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.

Active, not recruitingNCT06299319

Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial

Centre for Addiction and Mental Health

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
10 estimated
Locations
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Registry updated
2026-07-28
Open registry recordTracker record
RecruitingNCT07347405

A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Francisco A Moreno

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
30 estimated
Locations
The Clinical and Translational Sciences Research Center, Tucson, Arizona, United States
Registry updated
2026-07-23
Open registry recordTracker record
TerminatedNCT06624137

Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects

Yale University

Conditions
OCD · Major Depressive Disorder (MDD) · Alcohol Use Disorder (AUD) · Healthy Volunteer
Phase
Phase not reported
Enrollment
5 actual
Locations
Connecticut Mental Health Center, Hamden, Connecticut, United States · West Haven VA Medical Center, West Haven, Connecticut, United States
Registry updated
2026-07-09
Open registry recordTracker record
Active, not recruitingNCT05370911

Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study

Yale University

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
28 actual
Locations
Enact Research Collaborative (40 Temple St, 4th Floor), New Haven, Connecticut, United States · Yale Program for Psychedelic Research, New Haven, Connecticut, United States
Registry updated
2026-06-04
Open registry recordTracker record
Active, not recruitingNCT05546658

Effects of Psilocybin in Obsessive Compulsive Disorder

Johns Hopkins University

Conditions
Obsessive-Compulsive Disorder
Phase
Early Phase 1
Enrollment
35 actual
Locations
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Registry updated
2026-04-02
Open registry recordTracker record
RecruitingNCT06442423

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

Yale University

Conditions
Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
Phase
Phase 1
Enrollment
50 estimated
Locations
Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
Registry updated
2026-03-11
Open registry recordTracker record
RecruitingNCT04882839

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.

Beersheva Mental Health Center

Conditions
Obsessive-compulsive Disorder
Phase
Phase 2
Enrollment
15 estimated
Locations
Beer Sheva Mental Health Center, Beersheba, Israel
Registry updated
2025-11-19
Open registry recordTracker record
CompletedNCT03356483

Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.

Yale University

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
31 actual
Locations
Connecticut Mental Health Center, New Haven, Connecticut, United States
Registry updated
2024-11-20
Open registry recordTracker record
CompletedNCT06258031

PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)

Imperial College London

Conditions
Obsessive-Compulsive Disorder
Phase
Phase 1
Enrollment
19 actual
Locations
CIPPRes Clinic, London, United Kingdom
Registry updated
2024-11-06
Open registry recordTracker record
CompletedNCT03300947

Psilocybin for Treatment of Obsessive Compulsive Disorder

University of Arizona

Conditions
Obsessive-compulsive Disorder (OCD)
Phase
Phase 1
Enrollment
15 actual
Locations
University of Arizona, Tucson, Arizona, United States
Registry updated
2024-08-30
Open registry recordTracker record
Related research views

Move between curated condition, country, phase, and recruiting views without losing direct source provenance.

Recruitment

Conditions

Countries

Phases

Method and accountability

How this collection is maintained

Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.

Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.

Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.